Estimating drug costs in economic evaluations in Ireland and the UK: An analysis of practice and research recommendations

PharmacoEconomics

Volumn 27, Issue 8, 2009, Pages 635-643

  Hughes, Dyfrig A ^a   Tilson, Lesley ^b   Drummond, Michael ^c  

^a BANGOR UNIVERSITY   (United Kingdom)

^b National Centre for Pharmacoeconomics   (Ireland)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PROTON PUMP INHIBITOR; WARFARIN;

ANALYSIS; CHECKLIST; CLINICAL PRACTICE; CLINICAL RESEARCH; COMPARATIVE STUDY; DATA EXTRACTION; DRUG COST; ECONOMIC EVALUATION; EUROPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IRELAND; MEDICAL INFORMATION; MEDICAL LITERATURE; PRIORITY JOURNAL; REVIEW; SAMPLE; UNITED KINGDOM;

DRUG COSTS; ECONOMICS, PHARMACEUTICAL; GREAT BRITAIN; HUMANS; IRELAND; MODELS, ECONOMIC; RESEARCH DESIGN;

EID: 69749086196     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/10899570-000000000-00000     Document Type: Review

References (53)

1. Barbieri M, Drummond MF, Willke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005; 8 (1): 10-23 (Pubitemid 40293637)
2. Halliday RG, Darba J. Cost data assessment in multinational economic evaluations: some theory and review of published studies. Applied Health Econ Policy 2003; 2 (3): 149-155
3. Tarn TY, Smith MD. Pharmacoeconomic guidelines around the world, ISPOR Connections 2004; 10 (4): 5-12 [online]. Available from URL: http://www.ispor.org/News/articles/aug04/PEGuidelines.asp [Accessed 2009 Jun 29]
4. NHS EconomicEvaluationDatabase [online]. Available from URL: http://www.crd.york.ac.uk/ [Accessed 2009 Jun 29]
5. Centre for Reviews and Dissemination. NHS economic evaluation handbook. York: Centre for Reviews and Dissemination, University of York, 2007 Apr
6. Medicines.org.uk. Summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/ [Accessed 2009 Jun 19]
7. Guest JF, Clegg JP, Davie AM, et al. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. Curr Med Res and Opin 2005; 21(5): 805-815
8. Heart Protection Study Collaborative Group. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomized trial in 20536 individuals. Lancet 2005; 365: 1779-1785
9. McInnes G, Burke TA, Carides G. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study. J Hum Hypertens 2006; 20 (1): 51-58
10. Sander B, Gyldmark M, Hayden FG, et al. Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom. Eur J Health Econ 2005; 50: 244-252 (Pubitemid 41638848)
11. Joint Formulary Committee. British National Formulary. 56th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2008 Sep [online]. Available from URL: http://www.bnf.org/bnf/ [Accessed 2009 June 6]
12. Cassidy J,Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94 (8): 1122-1129
13. Shah T, Lai WK, Mutimer D. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus- seropositive donors. Transpl Infect Dis 2005; 7 (2): 57-62 (Pubitemid 41337791)
14. Swift J A, Conway P, Purdie DW. A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus. CurrMed Res Opin 2005; 21 (12): 2051-2061 (Pubitemid 41803115)
15. ValentineWJ, Palmer AJ, Lammert M, et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res and Opin 2005; 21 (12): 2063-2071 (Pubitemid 41803116)
16. MIMS. Monthly Index of Medical Specialities (MIMS). London: Haymarket Medical Ltd, 2009
17. Prescription Pricing Authority. The electronic drug tariff [online]. Available from URL: http://www.ppa.org.uk/ppa/edt-intro.htm [Accessed 2009 Jun 29]
18. Hughes D, Bodger K, Bytzer P, et al. Economic analysis of ondemand maintenance therapy with proton pump inhibitors in patients with nonerosive reflux disease. Pharmacoeconomics 2005; 23 (10): 1031-1041 (Pubitemid 41603436)
19. Wade AG, Toumi I, Hemels MEH. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005; 27 (4): 486-496 (Pubitemid 40732655)
20. Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Curr Med Res Opin 2005; 21 (7): 1005-1014 (Pubitemid 41032689)
21. CMP Medica Ltd. Chemist and Druggist. Monthly pricelist. Kent: CMP Medica Ltd., 2009
22. Green C, Dinnes J, Takeda AL, et al. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Int J Technol Assess Health Care 2006; 22 (1): 90-100 (Pubitemid 43376244)
23. Quilici S, Martin M, McGuire A, et al. A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients. Int J Clin Prac 2006; 60 (8): 922-932 (Pubitemid 44082283)
24. BriggsA H, Bousquet J,WallaceMV, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006; 61 (5): 531-536 (Pubitemid 43920150)
25. Roze S, Valentine WJ, Zakrzewska KE, et al. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabetic Medicine 2005; 22 (9): 1239-1245 (Pubitemid 41224186)
26. Lacey LA, Wolf A, O'shea D, et al. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes 2005; 29 (8): 975-982 (Pubitemid 41076238)
27. Walshe V, O'Morain C, Bennett K, et al. 'Best practice' for Helicobacter pylori eradication in the primary care setting. Ir Med J 2006; 99 (1): 11-12
28. MIMS Ireland. Monthly Index of Medical Specialities Ireland. Dublin: Irish Medical Times, 2009
29. Danish Medicines Agency [online]. Available from URL: http://www.medicinpriser.dk/ [Accessed 2009 Jul 30]
30. Bisgaard H, Price MJ, Maden C, et al. Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children. Chest 2001; 120 (6): 1835-1842 (Pubitemid 34053442)
31. Christensen PM, Brixen K, Gyrd-Hansen D, et al. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 2005; 96 (5): 387-396 (Pubitemid 40676593)
32. Frei A, Andersen S, Hole P, et al. A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain. J Pain Palliat Care Pharmacother 2003; 17 (2): 5-26 (Pubitemid 36988095)
33. Vindt HolmM, Gyldmark M, Holme Hansen E. Pharmacoeconomic assessment of oseltamivir in treating influenza-the case of otherwise healthy Danish adolescents and adults. Pharm World & Sci 2004; 26 (6): 339-345
34. Norwegian Medicines Agency, the Felleskatalogen [online]. Available from URL: http://www.felleskatalogen.no/ [Accessed 2009 Jul 30]
35. Hudry J, Rinne JO, Keränen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. Ann Pharmacother 2006; 40 (4): 651-657
36. Salo H, Pekurinen M, Granlund H, et al. An economic evaluation of intermittent cyclosporin A therapy versus UVAB phototherapy in the treatment of patients with severe atopic dermatitis. Acta Derm Venereol 2004; 84 (2): 138-141 (Pubitemid 38523749)
37. Lää ketietokeskus Oy. Finnish drug price list [online]. Available from URL: http://www.laaketietokeskus.fi/ [Accessed 2009 Jul 30]
38. Leivo T, Salomaa A, Kosunen TU, et al. Cost-benefit analysis of Helicobacter pylori screening. Health Policy 2004; 70 (1): 85-96 (Pubitemid 39092961)
39. Martikainen JA, Kivioja A, Hallinen T, et al. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. Pharmacoeconomics 2005; 23 (8): 803-815 (Pubitemid 41420427)
40. Jowett S, Bryan S,Murray E, et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol 2006; 134 (6): 632-639 (Pubitemid 44253607)
41. Lane JA, Murray LJ, Noble S, et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial. Br Med J 2006; 332: 1-6 (Pubitemid 43171698)
42. Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics 2004; 3: 49-61 (Pubitemid 39481912)
43. Cook Fretheim A, Aaserud M, Oxman AD. The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. BMC Health Serv Res 2003; 3 (1): 18 (Pubitemid 38783270)
44. Ward SE, Kaltenthaler E, Cowan J, et al. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 2006; 95 (1): 27-34 (Pubitemid 43980550)
45. Cookson R, Flood C, Koo B, et al. Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease. Br J Surg 2005; 92 (6): 700-706 (Pubitemid 40863188)
46. Pharmaceutical Services Negotiating Committee. Indicative income tables (based on October 2008 arrangements) [online]. Available from URL: http://www.psnc.org.uk/pages/national-contract-funding.html [Accessed 2009 Jun 29]
47. Department of Health. Payment by Results: guidance and tariff for 2008-2009. [online]. Available from URL: http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-081096 [Accessed 2009 Jun 29]
48. Department of Health and Children. Independent body on pharmacy contract pricing, June 2008 [online]. Available from URL: http://www.dohc.ie [Accessed 2009 Jun 29]
49. Barry M, Tilson L, Ryan R. Pricing and reimbursement of drugs in Ireland. Eur J Health Econ 2004; 5: 190-194
50. Agreement between the Irish Pharmaceutical Healthcare Association Ltd and the Health Service Executive on the supply terms, conditions and prices of medicines supplied to the health services (2006) [online]. Available from URL: http://www.dohc.ie/publications/ipha-agreement.html [Accessed 2009 Jun 29]
51. Hughes DA, Cowell W, Koncz T, et al. Methods for considering medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007; 10 (6): 498-509 (Pubitemid 350013268)
52. Hoyle M. Future drug prices and cost-effectiveness analyses. Pharmacoeconomics 2008; 26 (7): 589-602 (Pubitemid 351871554)
53. Walshe V, Nash A, Barry M. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease. Ir Med J 2006; 99 (5): 144-145 (Pubitemid 44270044)